

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: RavenQuest Biomed Inc.(the “**Issuer**”).

Trading Symbol: RQB

Number of Outstanding Listed Securities: 168,617,831

Date: Month of May 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On May 1st, Ravenquest Biomed Inc.'s George Robinson has resigned from his position as president, chief executive officer, chief financial officer and director of the company as of April 29, 2020. Mr. Robinson has also resigned from all subsidiaries under Ravenquest.

The company is working toward obtaining the books, records and historical documents of each subsidiary from Mr. Robinson. Mr. Robinson is holding all records in lieu of pay; the company believes it is against his fiduciary duty to shareholders and debt holders, and will be working to a solution to retrieving company property. Negotiations with creditors have since failed and the remaining director sees no prospect for the company's survival.

Following the resignation of Mr. Robinson, Jatinder Dhaliwal will assume the role of interim CEO and interim CFO of the company.

Usama Chaudhry has also resigned as a director of the board as of April 30, 2020. The company would like to thank Mr. Chaudhry for his efforts and wishes him well in his future endeavours.

The company was then halted and suspended there afterwards.

2. Provide a general overview and discussion of the activities of management.

Please refer to Item #1 for further details.

3. Describe and provide details of any new products or services developed or offered. for resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Refer to Item #1

8. Describe the acquisition of new customers or loss of customers.

None

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None

11. Report on any labour disputes and resolutions of those disputes if applicable.

The Company has been in communication with Workers Compensation in regards to the previously announced labour disputes.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None

14. Provide details of any securities issued and options or warrants granted.

Please refer to Item #1 for further details.

15. Provide details of any loans to or by Related Persons.

None

16. Provide details of any changes in directors, officers or committee members.

Please refer to #1

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Licensed Cannabis Industry exists in a developing regulatory environment. Upon completion of the proposed transactions the Issuer will be subject to the evolving legislation and regulations, specifically, the *Access to Cannabis for Medical Purposes Regulations* ("ACMPR"). The *Marihuana for Medical Purposes Regulations* ("MMPR"), the predecessor to the ACMPR, was declared invalid by the Federal Court of Canada on February 24, 2016 and the ACMPR was enacted on August 24, 2016, in order to replace the MMPR. There is no guarantee that the ACMPR will not be repealed or replaced in the future.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 5, 2020

Jatinder Dhaliwal
Name of Director or Senior
Officer

/s/ Jatinder Dhaliwal
Signature

Director
Official Capacity

| | | |
|---|--|---|
| <i>Issuer Details</i> Name of Issuer RavenQuest Biomed Inc. | For Month End May, 2020 | Date of Report YY/MM/DD 20/06/05 |
| Issuer Address #400 – 837 W. Hastings Street | | |
| City/Province/Postal Code Vancouver, BC V6C 3N6 | Issuer Fax No. | Issuer Telephone No. (604) 368-3551 |
| Contact Name Jatinder Dhaliwal | Contact Position CEO | Contact Telephone No. (604) 368-3551 |
| Contact Email Address dhaliwal.jat@gmail.com | Web Site Address www.rqbglobal.com | |